A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants.
In the June 15th issue of Genes & Development, Dr. Stuart Orkin (HHMI, Dana-Farber Cancer Institute, Children's Hospital Boston) and colleagues present a new mouse model of osteosarcoma.
As unlikely as it sounds, scientists at the Garvan Institute for Medical Research have shown that there is a link between prostate cancer and a higher risk of bone fracture.
According to the National Osteoporosis Foundation, osteoporosis affects some 25 million Americans annually, 80 percent of them women. Because the disease causes a thinning of the bone, it can lead to hip fractures, spinal fractures and a whole host of debilitating and sometimes deadly complications.
